Rescue of Interferon Induced Bone Marrow Aplasia in a Patient with Chronic Myeloid Leukemia by Allogeneic Bone Marrow Transplant

References

• Gutterman, J.U., Blumenschein, G.R., Alexanian, R., Yap, H.Y., Buzdar, A.U., Cabanillas, F., et al. (1980) "Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma", Annals of Internal Medicine, 93, 399–406.
   Google Scholar
• Quesada, J.R., Reuben, J., Manning, J.T., Hersh, E.M. and Gutterman, J.U. (1984) "Alpha interferon for induction of remission in hairy cell leukaemia", New England Journal of Medicine, 10, 15–18.
   Google Scholar
• Quesada, J.R., Swanson, D.A., Trindade, A. and Gutterman, J.U. (1983) "Renal cell carcinoma: Antitumor effects of leukocyte interferon", Cancer Research, 43, 940–943.
   Google Scholar
• Gutterman, J.U., Fine, S., Quesada, J., Horning, Si., Levine, J.F., Alexanian, R., et al. (1982) "Recombinant leukocyte A interferon: pharmacolcinetics, single-dose tolerance and biological effects in cancer patients", Annals of Internal Medicine, 96, 549–556.
   Google Scholar
• Ingimarsson, S., Cantell, K. and Strander, H. (1979) "Side effects of long term treatment with human leukocyte interferon", Journal of Infectious Disease, 140, 560–563.
   Google Scholar
• Scott, G.M., Secher, D.S., Flowers, D., Bate, J., Cantell, K. and Tyrrell, D.A. (1981) "Toxicity of interferon", British Medical Journal, 282, 1345–1348.
   PubMed Web of Science ®Google Scholar
• Urbaniak, S.J., Halliday, TM., Beveridge, G.W. and Kay, A.V. (1978) "Neutropenia and thrombocytopenia after repeated course of leukocyte interferon", Lancet, 1, 553–554.
   Google Scholar
• Ingimarrson, S., Bergstom, L.A., Cantell, K. and Strander, H. (1980) "Effects of long-term treatment with human leukocyte interferon on various laboratory parameters", Acta Medica Scandinavica, 208, 155–159.
   Google Scholar
• Talpaz, M., Kantarjian, H., Kurzrock, R. and Gutterman, J.U. (1992) "Bone marrow hypoplasia and aplasia complicating inter-feron therapy for chronic myelogenous leukemia", Cancer, 69(2), 410— 412.
   PubMed Web of Science ®Google Scholar
• Bacigalupo, A., Broccia, G., Corda, G., Arcese, W., Carotenuto, M., Gallamini, A., et al. (1995) "Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party", Blood, 85(5), 1348–1353.
   PubMed Web of Science ®Google Scholar
• Allan, N.C., Richards, S.M. and Shepherd, P.C.A. (1995) "UK Medical Research Council randomised, multicentre trial of inter-feron-an1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response", Lancet, 345, 1392–1397.
   Google Scholar
• Guilhot, F., Chastang, C., Michallet, M., Guerci. A., Harousseau, J.L., Maloisel, F., et al. (1997) "Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukae-mia", New England Journal of Medicine, 337, 223–229.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H.M., Smith, T.L., O'Brien, S., Beran, M., Pierce, S. and Talpaz, M. (1995) "Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a therapy", Annals of Internal Medicine, 122, 254–261.
   Web of Science ®Google Scholar
• Sacchi, S., Kantarjian, H.M., Smith, T.L., O'Brien, S., Pierce, S., Kornblau, S., et al. (1998) "Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukaemia", Journal of Clinical Oncology, 16, 882–889.
   PubMed Web of Science ®Google Scholar
• Silver, R.T., Woolf, S., Hehlmann, R., Appelbaum, F., Anderson, J., Bennett, C., et al. (1999) "An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogenic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology", Blood, 94(5), 1517–1536.
   PubMed Web of Science ®Google Scholar
• Zoumbos, N.C., Gascon, P., Dieu, J.Y. and Young, N.S. (1984) "Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo", Proceedings of the National Academy of Sciences of the United States of America, 82,188–192.
   Google Scholar
• Zoumbos, N.C., Gascon, P., Deu, J.Y., Trost, S.R. and Young, N.S. (1985) "Circulating activated suppressor T lymphocytes in aplastic anemia", New England Journal of Medicine, 312, 57–65.
   Google Scholar
• Mangan, K.F., Zidar, B., Shadduck, R.K., Zeigler, Z. and Winkelstein, A. (1985) "Interferon-induced aplasia: evidence for T-cell-mediated suppression of hematopoiesis and recovery after treatment with horse antihuman thymocyte globulin", American Journal of Hematology, 19(4), 401–413.
   PubMed Web of Science ®Google Scholar
• Gazitt, Y., Ben-Bassat, H., Wallack, D., Revel, M. and Schattner, A. (1984) "Interferon-induced cytotoxicity and 2'5'-oligo (A) synthetase activity in T cells. Differences in responsiveness among T cells from various individuals among lymphoblastoid T cell lines", Clinical Immunology and Immunopathology, 30(1), 71–79.
   Google Scholar
• Shattner, A., Merlin, G., Wallach, D., Rosenberg, H., Bino, T., Hahn, T., et al. (1981) "Monitoring of interferon therapy by assay of 2'5'-oligo-isoadenylate synthetase in human peripheral white blood cells", Journal of Interferon Research, 1(4), 587–594.
   PubMedGoogle Scholar